MarketPulse

Phase 3 VALOR trial

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Priovant Therapeutics / Roivant Sciences

Priovant's Brepocitinib Clears Phase 3 Trial for Rare Muscle Disease, Eyes 2026 FDA Approval

Priovant's brepocitinib met Phase 3 endpoints for dermatomyositis treatment, earning FDA Priority Review with Q3 2026 decision expected.
ROIVclinical trial resultsautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Valneva Plunges 37% After Lyme Vaccine Fails Phase 3 Trial; Law Firm Launches Investigation

Valneva stock plummets 37% after Phase 3 Lyme vaccine candidate fails trial; law firm investigates potential securities fraud claims.
PFEVALNsecurities fraudstock price decline